Epstein Secrets

Efficacy Standards For Vaccine. The Washington Post (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safe

es: chief Executive David Solomon, President John Waldron, Chief Financial Officer Stephen Scherr and the head of Goldman's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein an

0/22/covid-vaccine-safety-effectiveness- guidelines/> (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safet

es: chief Executive David Solomon, President John Waldron, Chief Financial Officer Stephen Scherr and the head of Goldman's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein and

Efficacy Standards For Vaccine. The Washington Post (10/22, McGinley, Johnson, 14.2M) reports that vaccine experts on Thursday "rigorously debated the Food and Drug Administration's planned standards for clearing a coronavirus vaccine quickly for broad use, discussing what level of evidence would be sufficient to establish safe

ves: chief Executive David Solomon, President John Waldron, Chief Financial Officer Stephen Scherr and the head of Goldman's international business, Richard Gnodde will give up $31 million in pay this year. In addition, the bank will take back millions in past pay from Solomon's predecessor, Lloyd Blankfein an